Barrett M P, Fairlamb A H
Division of Infection and Immunity, Institute of Biomedical and Life Sciences, University of Glasgow, Glasgow, UK.
Parasitol Today. 1999 Apr;15(4):136-40. doi: 10.1016/s0169-4758(99)01414-3.
Resistance to currently used drugs is a serious problem in most fields of antimicrobial chemotherapy. Crossresistance between two of the major classes of drug used in the treatment of African trypanosomiasis, the melaminophenyl arsenicals and diamidines is easily selected in the laboratory. Here, Mike Barrett and Alan Fairlamb outline the mechanism underlying this crossresistance, which appears to arise as a result of alterations in an unusual adenosine transporter involved in the uptake of these drugs.
在抗微生物化疗的大多数领域，对目前使用的药物产生耐药性是一个严重问题。在治疗非洲锥虫病时使用的两类主要药物—— melaminophenyl砷剂和双脒类药物之间的交叉耐药性，在实验室中很容易被筛选出来。在此，迈克·巴雷特和艾伦·费尔兰姆概述了这种交叉耐药性背后的机制，这种机制似乎是由于参与这些药物摄取的一种特殊腺苷转运体发生改变而产生的。
